Parkinson’s disease （PD） is a kind of neurodegenerative diseases of the central nervous system in which substantia nigra neurons are damaged and necrotic. At present，PD is mainly treated with drugs which affect the key molecular in the pathogenesis of PD or signaling pathway to alleviate the disease，however，denatured neuron could not be completely repaired. In recent years，cell therapy technology has gradually infiltrated into clinical trials and became a social focus. Bone marrow mesenchymal stem cells（BMSCs），a kind of adult pluripotent stem cells，have self-proliferation and multi-directional differentiation capabilities and are applied to explore more effective strategies for PD treatment. Astragaloside IV，a characteristic component of traditional Chinese medicine Astragalus，possesses anti-inflammatory，anti-oxidative and antiapoptotic activities. What’s more，Astragaloside IV has a protective effect on neural stem cells，and the study demonstrated that Astragaloside IV plays a neuroprotective role in PD model. This article reviewed the research progress of BMSCs and Astragaloside IV in the treatment of PD. A new idea that Astragaloside IV induced BMSCs to treat PD is proposed based on above of conclusions.